Blog

Jun 19, 2025, 16:21

Neeraj Agarwal: Poor Outcomes with SOC in mHSPC Prostate Cancer Patients With HRR Mutation

Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on X:

“Just in Clinical Cancer Research AACR

Congrats Chadi Hage Chehade, Umang Swami and Huntsman GU team

Poor outcomes with SOC Rx in mHSPC prostate cancer with HRRm in 637 real-world US patients

need to add PARPi”

MHSPC prostate cancer

Title: Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Authors: Chadi Hage Chehade, Ryon P. Graf, Zeynep Irem Ozay, Georges Gebrael, Nicolas Sayegh, Gerald Li, Benjamin L. Maughan, Emmanuel S. Antonarakis, Rana R. McKay, Neeraj Agarwal, Umang Swami

Read Full Article.

Neeraj Agarwal: Poor Outcomes with SOC in mHSPC Prostate Cancer Patients With HRR Mutation

More posts featuring Neeraj Agarwal on OncoDaily.

Benjamin L Maughan cancer Chadi Hage Chehade Emmanuel S Antonarakis Georges Gebrael Gerald Li Neeraj Agarwal Nicolas Sayegh OncoDaily Oncology prostate cancer Rana R. McKay Ryon P. Graf Umang Swami Zeynep Irem Ozay

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More